Discontinuing Long‐Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?

Documenti analoghi

• Denosumab Offers Relatively Lower Initial Protection Against Osteoporotic Vertebral Fractures in Treatment‐Naive Patients Compared With Zoledronate
  di: Ko‐Hsiu Lu, et al.
  Pubblicazione: (2026)
• Therapeutic Strategies of Denosumab Sequential Therapy: A Four‐Armed Randomized Controlled Trial
  di: Hung‐Kuan Yen, et al.
  Pubblicazione: (2025)
• Long‐Term Follow‐Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss
  di: Simon J. Hume, et al.
  Pubblicazione: (2025)
• The Impact of QT‐Prolonging Medications and Drug–Drug Interactions on QTc Interval Prolongation in Hospitalized Patients: A Case‐Crossover Study
  di: Hsiu‐Ting Chien, et al.
  Pubblicazione: (2024)
• Air Pollution Associated With Mortality Among Chronic Hepatitis B Patients Treated With Nucleotide/Nucleoside Analogues
  di: Tyng‐Yuan Jang, et al.
  Pubblicazione: (2025)